Pharma Focus Asia

Ascentage Pharma Announces U.S. FDA Acceptance of IND Application for Clinical Study of Novel IAP Inhibitor APG-1387

Thursday, November 16, 2017

Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for APG-1387, a novel small molecule IAP inhibitor for the treatment of advanced solid tumors and hematologic malignancies.

Inhibitors of apoptosis (IAPs) are a group of proteins that act on the intrinsic pathway that blocks programmed cell death or apoptosis. High expression of IAP proteins has been linked to several cancers, including lung, head and neck, breast, gastrointestinal, and melanoma and multiple myeloma. APG-1387 is designed to bind to IAP protein monomers and dimers, unlike other IAP inhibitors in development which bind only to monomers. The Company believes that this dual inhibition may improve its effectiveness for more cancers. Ascentage has previously completed Phase 1 dose escalation studies with APG-1387 in China and Australia.

"The acceptance of a U.S. IND application represents another important milestone in the global clinical development of APG-1387," said Dr. Yang Dajun, Chairman and CEO of Ascentage. "Based on preclinical and clinical results achieved to date, we believe APG-1387 could represent a first-in-class treatment option for patients with a wide range of refractory or resistant cancers."

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024